Full-Time
Senior Plant Controller
Updated on 9/3/2026
Hovione
1,001-5,000 employees
CDMO for complex drug APIs manufacturing
Compensation Overview
$105.7k - $169.1k/yr
East Windsor, NJ, USA
In Person
Bachelor's
 Accounting (1) |
|---|
Get referred to Hovione
See people who can refer or advise you
- A university or equivalent qualification in Finance, Business Administration, or a similar field is mandatory.
- Typically requires 5–8 years of relevant experience as a controller or financial auditor.
- Experience applying International Financial Reporting Standards.
- Advanced knowledge of finance and accounting with the ability to solve complex problems.
- Advanced knowledge of reporting tools.
- Knowledge of corporate governance.
- Fluency in English is required.
- Computer literacy and good working knowledge of the Microsoft Office package are required.
- Support Finance and the business as a business partner.
- Define and implement business processes that assess overall performance, identify business drivers, benchmark against relevant key performance indicators, identify improvement opportunities, and promote business process optimization.
- Define, produce, and challenge timely reports addressing performance against budget, profitability, cost, efficiency, and risk.
- Prepare, monitor, and control the annual departmental budget to ensure expenditure aligns with the company business plan.
- Administer departmental financial and operational information in the appropriate systems.
- Develop and monitor business performance metrics for the department while partnering with managers and directors and understanding strategic challenges.
- Execute regular and specific complex reports for the department related to operational and financial key performance indicators as requested by managers and directors.
- Conduct forecasts using financial and operational information.
- Support department project managers by analyzing project costs to ensure budgeted costs comply with requirements.
- Conduct department-specific analyses to improve data reporting and analysis.
- Provide financial and accounting advice to department directors and managers.
- Master controlling processes and tools.
- Manage complex projects and analyses with significant business impact.
- Make timely, high-quality decisions based on multiple data sources.
- Manage risk and uncertainty and anticipate and escalate roadblocks to prevent deviations from goals.
- Perform professional activities in compliance with Good Manufacturing Practice and health, safety, and environmental guidelines, internal and external requirements, and promote implementation and maintenance of company policies, systems, and procedures.
Hovione is a contract development and manufacturing organization that helps pharmaceutical companies develop and manufacture active pharmaceutical ingredients (APIs). It specializes in complex chemistry and manufacturing techniques such as particle engineering and spray drying to improve how drugs are absorbed. The company stands out through a long history, a focus on difficult-to-make compounds, and a global footprint with FDA-inspected sites in Portugal, Ireland, China, and the United States, built from a private, family-owned background. Its goal is to enable partners to bring new medicines to market efficiently by providing high-quality, scalable manufacturing capacity and continuous investment in capabilities.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Loures, Portugal
Founded
1959
Get referred to Hovione
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 2026 Loures expansion added 25% commercial tableting capacity and 50 skilled jobs.
- New Jersey's $100 million build doubled U.S. spray-drying capacity, with GMP launch in Q2 2026.
- Seixal's €200 million campus opens in 2027, expanding capacity for export-heavy customers.
What critics are saying
- May 2026 CEO Jean Luc Herbeaux resigned; Hovione still runs under interim co-CEOs.
- Customer concentration is severe; one quality failure can jeopardize 19 top-pharma relationships.
- A single FDA remediation failure at East Windsor would freeze U.S. supply and crater growth.
What makes Hovione unique
- Hovione owns integrated spray drying, tableting, and particle engineering across Loures, New Jersey, and Seixal.
- Its August 2026 Loures mirror-line design enables validated product transfers without reformulation or redevelopment.
- Hovione serves 19 of the world’s 20 largest pharma companies from five manufacturing sites.
Help us improve and share your feedback! Did you find this helpful?
Company News
Hovione completes €40 million expansion of Loures tablet manufacturing center. Expansion strengthens integrated manufacture of amorphous solid dispersions (ASDs) by spray drying and tableting at a single site, accelerating development and simplifying supply. Hovione, a global pharmaceutical CDMO, has completed the expansion of the company's tablet development and manufacturing center at its main global campus in Loures, Portugal, adding 25% more commercial-scale batch tableting capacity for the integrated supply of oral solid dosage products. The recently inaugurated expansion completes an investment cycle of more than €40 million. Hovione expanded its batch tableting capacity by adding an additional line mirroring the original unit across every local operation: dispensing, blending, dry granulation, and tableting and film coating. The mirrored configuration reinforces capacity at the 300 to 400 kg batch scale and provides both redundancy and like-for-like product transfers between lines, reducing the process risk that typically accompanies the move from development into commercial supply. Supporting areas, including in-process control and staging space sized to the increased production capacity, were also added as part of the expansion. The added capacity strengthens Hovione's ability to manufacture ASDs by spray drying and tablet them into finished oral dosage forms at a single site. Executing both steps within one quality system compresses development timelines and simplifies supply chains for customers who would otherwise transfer intermediates between sites and/or suppliers. Demand for the single-site service continues to grow as ASD by spray drying remains a vital solution for poor solubility that slows development timelines for over 70% of new molecular entities. "This investment completes our existing capabilities in Portugal and strengthens the competitiveness of our operations. It gives us greater scale and flexibility to respond to the needs of an industry that is seeking to develop new medicines more quickly and build more resilient supply chains closer to its markets. This is an important step in continuing to support our customers internationally," said António Almeida and Marco Gil, Co-CEOs of Hovione. In 2022, Hovione invested in a next-generation continuous tablet manufacturing line at the same industrial complex. As pharmaceutical companies increasingly evaluate continuous manufacturing alongside established batch processes, Hovione has continued to invest in resilient manufacturing infrastructure that supports both current customer needs and future demand. "Mirroring the line rather than simply adding equipment was a deliberate choice," said Jorge Pastilha, VP of Technical Operations for Europe and Asia at Hovione. "It means a product validated on one line can move to the other without reformulation or process redevelopment, which gives customers continuity of supply." Company. Sete Casas 2674-506 Loures Portugal
Continuous Manufacturing Forum 2026. Tuesday, September 22, 2026 Wednesday, September 23, 2026 Location: New Jersey, United States Continuous Tableting is no longer experimental - it is regulated, commercially proven, and rapidly scaling. This September 22-23, Hovione experts will join industry peers at the Continuous Manufacturing Forum (CMF) in Princeton, New Jersey, for two days of scientific exchange focused on the practical implementation of continuous manufacturing in the pharmaceutical industry. This is a must-attend event for those looking to explore the innovations, strategies, and collaborations transforming pharmaceutical production. Join the sessions led by its experts in Continuous Tableting. "The Evolution of Clinical Continuous Manufacturing: From Early Adoption to Operational Maturity" with Anthony Tantuccio "Disrupting the Granulation Paradigm: Enabling Direct Compression of Spray-Dried Dispersions Through Particle Design" with Sarang Oka | Anthony Tantuccio Fellow of Continuous Tableting at Hovione | Sarang Oka Production Senior Manager, Drug Product Continuous Manufacturing | As a first mover CDMO in Continuous Tableting, its team will be available to share firsthand insights into how Hovione can seamlessly integrate CT into your drug product development. Read its latest CT articles: Hovione - The future is continuous.
Hovione planning ribbon-cutting at NJ facility - A behind-the-scenes preview. The company is building out more than 200,000 square feet of space in New Jersey. July 31, 2026 Content Marketing Editor Topics.
Hovione invests 200 million in new medicine factory in Seixal by 2027. On the sidelines of the inauguration of a new production line at the group's campus in Loures, the final stage of a 40 million euro investment cycle, the co-CEOs of Hovione revealed that the development of the group's two industrial complexes has been entirely financed by equity. Hovione is investing 200 million euros in a new unit for the manufacture of medicines in Seixal, in the district of Setúbal, with opening scheduled for September 2027, announced the heads of the Portuguese chemical and pharmaceutical group this Tuesday. On the sidelines of the inauguration of a new production line at the group's campus in Loures, the final stage of a 40 million euro investment cycle, the co-CEOs of Hovione revealed that the development of the group's two industrial complexes has been entirely financed by equity. "We are in the Lisbon region and are a large company, so European funds do not reach us. It is a matter of legislation," said co-CEO António Almeida. As for the Seixal project, although it is located in Greater Lisbon, "it will be covered by the next European framework, from 2028 onwards, but patients cannot wait," added the same official. Despite not having access to European funds, at least in the first phase of the investment, Seixal was chosen to install Hovione's new industrial complex because "it is close to an airport." "Our clients are international, we export all production and we wanted to be close to a center where we could export and easily receive visits," said, in turn, co-CEO Marco Gil, adding that another factor that weighed in the choice was the proximity to Hovione's Research and Development center located in Lumiar, Lisbon. "When we think about these investments, we don't think in terms of 10, 15, 20 years, but rather 50, 60 years. In Seixal, we found a site that had the industrial characteristics necessary for our activity, which allows us to add other technologies, have a much larger scale, and access talent in the Lisbon region but also on the south bank." With the 25% extension of the productive area inaugurated today, Hovione has reached the physical limit of the Loures campus, so the increase in production capacity will pass through the future Seixal complex. The new tablet development and production line will add 50 new skilled jobs to the Loures campus, which already employs around 1,250 workers. With this investment, the Loures campus is strengthened as the main industrial, scientific and technological center of Hovione's global network, which includes among its clients 19 of the 20 largest pharmaceutical companies in the world. Most of Hovione's production is exported abroad, with the USA as the main destination. According to group officials, at least one in every ten medicines approved by the US regulator FDA are produced by Hovione for client pharmaceutical companies. During the inauguration ceremony, where the presidents of AICEP, Madalena Oliveira e Silva, and of the Loures City Council, Ricardo Leão, were also present, the Minister of Economy highlighted the fact that Hovione produces for some of the most sophisticated markets in the world and considered that the pharmaceutical sector "is a strategic sector for Portugal." "The disruptions in international supply chains highlighted the need to strengthen European industrial capacity in essential areas in the field of medicines and health products. It was with this concern that the Government integrated into the PRR measures aimed at strengthening the pharmaceutical sector," he further said. The chemical and pharmaceutical group Hovione was founded more than six decades ago in Portugal by Ivan Villax and Diane Villax. It has four factories in the USA, Portugal, Ireland, and China and development laboratories in Lisbon, Portugal and New Jersey (USA), employing more than 2,600 workers.
CRS 2026 Annual Meeting. Monday, July 06, 2026 Thursday, July 09, 2026 Location: Lisbon, Portugal Hovione is presenting at the CRS 2026 Annual Meeting, taking place in Lisbon, Portugal. The conference will explore groundbreaking advancements and transformative ideas in controlled release science and technology. Join the Hovione team for an inspiring week of insightful presentations, engaging discussions, and unparalleled networking opportunities with leading experts and innovators from around the world. Don't miss the chance to speak with its experts and learn how Hovione Scientia Ltd is advancing a differentiated offering in Biologics and Complex Injectables, from early development through to cGMP supply. Hovione Technical Forum. Rational Formulation Strategies for High Concentration Subcutaneous Biologics: From Innovative Excipients to Spray Dried Drug Product Suspensions July 7, 9:00-10:00 AM (WEST) Joana Cristóvão, Ph.D. R&D, Analytical Senior Manager Inês Matos, Ph.D.| R&D, Inhalation & Advanced Drug Delivery Manager Innovative formulation and manufacturing strategies are accelerating the shift from intravenous (IV) to patient-friendly subcutaneous (SC) delivery of biologics. This transition is driven by strong patient preference, reduced healthcare burden, and the opportunity for at-home administration. But challenges remain, especially for high-dose biologics. At the Hovione Technical Forum, in a single session, two complementary presentations will showcase how advanced formulation science and particle engineering are expanding the possibilities for efficient, scalable, and patient-centric biologic therapies: * Learn more about novel excipient design strategies to reduce viscosity and enhance stability in high-concentration liquid formulations * Get insights on spray drying as an enabling technology for biologics, unlocking new solid-state and ultra-concentrated formats Oral presentation. Addressing Nasal Delivery Challenges: Integrated Formulation and Device Strategies for Predictive Performance July 8, 2:53 PM - 3:16 PM WEST Patrícia Henriques, Ph.D. Scientist, Inhalation and Advanced Drug Delivery POSTERS & poster presenter. * (113) Looking Beyond Aerodynamics: Evaluation of Fluticasone Furoate via Dissolution and Permeation using Lung ALIs Beatriz Gamelas, M.Sc.| Ph.D. Candidate, Analytical Development * (132) Why Model Structure Matters: Translatability Across Inhalation PBPK Frameworks Filipa Ferreira, Pharm.D., Ph.D. Senior Scientist II, Translational Lead | Innovation * (502) Innovative Synthetic Sugars for Stable, Low-viscosity High-Concentration Biologic Formulations Joana Cristóvão, Ph.D. R&D, Analytical Senior Manager * (655) Optimizing CRISPR/Cas9 Polymeric Nanoparticle Formulations: From In Silico Insights to Microfluidics and Stability Strategies Andreia Sofia Pereira | Student, Inhalation and Advanced Drug Delivery * (655) CRISPR/Cas9 Nanoparticle Formulations: From In Silico Insights to Microfluidics and Stability Strategies Ask Hovione Scientia Ltd how Hovione Scientia Ltd is advancing more patient centric therapies through proprietary excipients, such as synthetic sugars, and spray dried approaches that unlock alternative dosage forms.